Tax First-line Chemotherapy With Different Doses and Then Maintenance Therapy (TFINE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01038661

Recruitment Status : Completed

First Posted : December 24, 2009

Last Update Posted : February 28, 2014

View this study on the modernized ClinicalTrials.gov

Sponsor:

Information provided by (Responsible Party):

Sanofi

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Completed
Actual Primary Completion Date :	August 2012
Actual Study Completion Date :	August 2012

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Zhang L, Lu S, Cheng Y, Hu Z, Wu YL, Chen Z, Chen G, Liu X, Yang J, Zhang L, Chen J, Huang M, Tao M, Cheng G, Huang C, Zhou C, Zhang W, Zhao H, Sun Y. Docetaxel maintenance therapy versus best supportive care after first-line chemotherapy with different dose docetaxel plus cisplatin for advanced non-small cell lung cancer (TFINE study, CTONG-0904): an open-label, randomized, phase III trial. Ann Transl Med. 2021 Feb;9(4):338. doi: 10.21037/atm-20-8078.

To Top